アルツハイマー治療薬のグローバル市場(2014-2018)...市場調査レポートについてご紹介

【英文タイトル】Global Alzheimer's Drugs Market 2014-2018

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Dementia
06.2 Epidemiology & Forecast (2013-2018)
06.3 Types of Dementia
07. Alzheimer’s Disease
07.1 A Global Burden
07.2 Etiology
07.3 Cost of Care
07.4 Alzheimer’s Disease & Caregiving
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by MOA
09.1.1 AChE Inhibitors
09.1.2 Glutamate Inhibitors
10. Market Assessment of Top Drugs
10.1 Aricept
10.1.1 Sales
10.1.2 Key Regulatory Approvals and Agreements
10.1.3 US Spending by Various Channels 2010-2013
10.2 Exelon
10.2.1 Sales
10.2.2 Key Regulatory Approvals and Agreements
10.2.3 US Spending by Various Channels 2010-2013
10.3 Namenda
10.3.1 Sales
10.3.2 Key Regulatory Approvals and Agreements
10.3.3 US Spending by Various Channels 2010-2013
10.4 Radazyne
10.4.1 Sales
10.4.2 Key Regulatory Approvals and Agreements
11. Competitive Assessment of Top Drugs
12. Focus on Alzheimer’s Research
12.1 National Alzheimer’s Project Act
12.2 Clinical Pipeline
13. Geographical Segmentation
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.2 Market Share Analysis 2013
22. Future Vendors Expected To Tap the Market
23. Key Vendor Analysis
23.1 Eisai Co., Ltd.
23.1.1 Key Facts
23.1.2 Business Overview
23.1.3 Sales by Geography
23.1.4 Revenue Comparison
23.1.5 Sales by Geography
23.1.6 Business Strategy
23.1.7 Key Information
23.1.8 SWOT Analysis
23.1.9 Strengths
23.1.10 Weaknesses
23.1.11 Opportunities
23.1.12 Threats
23.2 Forest Laboratories Inc.
23.2.1 Key Facts
23.2.2 Business Overview
23.2.3 Business/Product Segmentation
23.2.4 Product Segmentation by Revenue 2013
23.2.5 Business/Products Segmentation by Revenue 2012 and 2013
23.2.6 Sales by Geography
23.2.7 Business Strategy
23.2.8 Key Information
23.2.9 SWOT Analysis
23.2.10 Strengths
23.2.11 Weaknesses
23.2.12 Opportunities
23.2.13 Threats
23.3 Janssen Pharmaceuticals Inc.
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Product Segmentation
23.3.4 Business Strategy
23.3.5 Key Information
23.3.6 SWOT Analysis
23.3.7 Strengths
23.3.8 Weaknesses
23.3.9 Opportunities
23.3.10 Threats
23.4 Novartis AG
23.4.1 Key Facts
23.4.2 Business Description
23.4.3 Business Segmentation
23.4.4 Revenue by Business Segmentation
23.4.5 Revenue Comparison 2012 and 2013
23.4.6 Sales by Geography
23.4.7 Business Strategy
23.4.8 Key Developments
23.4.9 SWOT Analysis
23.4.10 Strengths
23.4.11 Weaknesses
23.4.12 Opportunities
23.4.13 Threats
24. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Projected Prevalence of Dementia by Regions 2013-2050 (in millions)
Exhibit 3: Projected Prevalence of Dementia by Regions 2013-2018 (in millions)
Exhibit 4: Types of Dementia by Prevalence 2013
Exhibit 5: Alzheimer’s Disease and Other Dementias Burden by Geographical Segmentation (Annually) 2013
Exhibit 6: Costs of Care by Payer for Americans Age 65 and Older with Alzheimer‘s Disease and Other Dementias 2013
Exhibit 7: Distribution of Alzheimer’s Caregivers by Age, 2013
Exhibit 8: Projected Prevalence of dependence in 2030 (in percent)
Exhibit 9: Global Alzheimer’s Disease Drugs Market 2013-2018 (US$ billion)
Exhibit 10: Global Alzheimer’s Drugs Market Segmentation by MOA
Exhibit 11: Eisai Co. Ltd.’s Aricept Revenue FY1996-FY2013 (US$ million)
Exhibit 12: Eisai Co. Ltd.’s Aricept Geography-wise Revenue FY1996-FY2010 (US$ million)
Exhibit 13: Eisai Co. Ltd.’s Aricept Geography-wise Revenue FY2011-FY2013 (US$ million)
Exhibit 14: Key Event Timeline of Aricept Formulations
Exhibit 15: Timeline for Aricept Formulations in US and Europe
Exhibit 16: US Spending on Aricept by Various Channels 2010-2013
Exhibit 17: Novartis AG’s Exelon Revenue 2001-2013 (US$ million)
Exhibit 18: Novartis AG’s Exelon Geography-Wise Revenue 2001-2013 (US$ million)
Exhibit 19: Key Event Timeline of Exelon Formulations
Exhibit 20: US Spending on Exelon by Various Channels 2010-2013
Exhibit 21: Forest’s Namenda Revenue 2004-2014 (FY ending March 2014) (US$ million)
Exhibit 22: Key Event Timeline of Namenda Formulations
Exhibit 23: US Spending on Namenda by Various Channels 2010-2013
Exhibit 24: Razadyne Revenue 2007-2009 (US$ million)
Exhibit 25: Key Event Timeline of Razadyne
Exhibit 26: Sales of Top 3 Alzheimer’s Drugs FY 2004-2013 (US$ million)
Exhibit 27: Sales of Top 3 Alzheimer’s Drugs 2004-2013 (US$ million)
Exhibit 28: Alzheimer’s Disease Research Projects by NIH Institutes and Centers 2011
Exhibit 29: NIH funded Alzheimer’s Disease Research Projects by CADRO topic 2011
Exhibit 30: Classification of Disease Modifying Pipeline Molecules by MOA
Exhibit 31: Clinical Trials of Alzheimer’s Disease by Phase 2013
Exhibit 32: Clinical Trials of Alzheimer’s Disease by Recruitment Status 2013
Exhibit 33: Promising Late Stage Pipeline Molecules 2013
Exhibit 34: Global Alzheimer’s Drugs market by Geographical Segmentation 2013
Exhibit 35: 65+ Global Population 2014-2018 (in million)
Exhibit 36: Global Alzheimer’s Drugs Market Share Analysis 2013
Exhibit 37: Eisai Co., Ltd.: Geographical Segmentation of Revenue for 2013 and 2012(US$ billion)
Exhibit 38: Eisai Co., Ltd.: Revenue comparison for the last 3 years (US$ billion)
Exhibit 39: Eisai Co., Ltd.: Sales by Geography for 2013 (US$ billion)
Exhibit 40: Forest Laboratories Inc.: Product Segmentation (by therapeutic areas) 2013
Exhibit 41: Forest Laboratories Inc.: Product Segmentation by Revenue 2013
Exhibit 42: Forest Laboratories Inc.: Product Segmentation by Revenue 2012 and 2013(US$ million)
Exhibit 43: Company Name: Sales by Geography 2013
Exhibit 44: Janssen Pharmaceuticals, Inc.: Product Segmentation 2013
Exhibit 45: Novartis AG: Business Segmentation
Exhibit 46: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 47: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 48: Novartis AG: Revenue by Geographical Segmentation 2013


【レポート販売概要】

■ タイトル:アルツハイマー治療薬のグローバル市場(2014-2018)
■ 英文:Global Alzheimer's Drugs Market 2014-2018
■ 発行日:2014年6月20日
■ 調査会社:Technavio
■ 商品コード:IRTNTR3675
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。